CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin
- Wednesday, May 19, 2021, 7:14
- Environment
- Add a comment
HOUSTON, May 19, 2021 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced open…
About the Author
adminasapcorp has written 41790 stories on this site.